SEARCH RESULT

Total Matching Records found : 105

Drug makers suffer an overdose of control-Bhupesh Bhandari

-The Business Standard The new price caps for 191 essential drugs are likely to introduce serious distortions in the market for these medicines The National Pharmaceutical Pricing Authority, or NPPA, has announced new price caps for 191 essential drugs that are 10 to 50 per cent lower than the current prices. Drug makers have 45 days to recall the earlier batches and send out new ones with the lower price tags. This...

More »

Environment ministry ignores states' opposition, approves GM trials -Nitin Sethi

-The Times of India NEW DELHI: The environment ministry's Genetic Engineering Appraisal Committee (GEAC) has cleared field trials for genetically modified rice, wheat, maize and castor for the Kharif season of 2013. The clearances - some of them extension of existing clearances that stood to lapse with state governments opposing field trials and others for relocating trial sites - come while the Biotechnology Regulatory Authority of India Bill is pending before the...

More »

In the ‘pharmacy of the world’ -PT Jyothi Datta

-The Hindu Business Line From maker of versions of drugs, India's pharmaceutical industry has turned a top innovator Twenty years ago, Ranbaxy was a home-spun drug-maker. The Indian Patents Act allowed companies to make chemically-similar versions of innovative drugs. Visionaries in the pharmaceutical sector, like Parvinder Singh (Ranbaxy's key architect and member of its promoter family) and Anji Reddy (founder of Dr Reddy's Laboratories), were alive. And the pharmaceutical industry did not have...

More »

The Larger Implications of the Novartis Glivec Judgment-Sudip Chaudhuri

-Economic and Political Weekly The Supreme Court judgment on the Novartis-Glivec case is remarkable because it has gone beyond the specific technical and legal issues surrounding patents and has put the matter in a much larger political and economic perspective. The deeper implication of the judgment is that it is not only justified to deny patents when incremental innovation is trivial as in the Glivec case. The judgment has linked the...

More »

2,644 died during clinical trial of drugs in 7 years: Govt to SC -Dhananjay Mahapatra

-The Times of India As many as 2,644 people, called subjects, died during the clinical trials of 475 new drugs on human beings in last seven years and only 17 of the medicines were approved for marketing in India, the Centre has informed the Supreme Court. Responding to allegations by NGO, Swasthya Adhikar Manch, in its PIL that Indians were used as guinea pigs by foreign pharmaceutical majors for human trial of...

More »

Video Archives

Archives

share on Facebook
Twitter
RSS
Feedback
Read Later

Contact Form

Please enter security code
      Close